Progyny (PGNY) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

While trading ideas are certainly important—whether in arbitrage, relative value, or directional trading—the true determinant ...

Contrary to the beliefs of some in the anti-vaxx world, infectious diseases spread through bacteria and viruses, microscopic ...

Predicting who will develop type 1 diabetes is now cheaper and more accessible, thanks to a new tool based on research ...

Investors might want to bet on Daktronics (DAKT), as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of the ...

Recent headlines about the chemical industry are concerning, but they should serve as a call to action for government, ...

SACRAMENTO, CA / ACCESS Newswire / December 11, 2025 / In the high-stakes arena of enterprise change, where billions in capital and countless careers hinge on the outcome, failure is a familiar ...

A systematic review of 36 studies from low- and middle-income countries has revealed a strong link between indoor air ...

Elicio Therapeutics (ELTX) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings ...